Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice
Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown th...
Saved in:
Main Authors: | Sílvia Castany (Author), Xavier Codony (Author), Daniel Zamanillo (Author), Manuel Merlos (Author), Enrique Verdú (Author), Pere Boadas-Vaello (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intradermal Treatment with a Hyaluronic Acid Complex Supplemented with Amino Acids and Antioxidant Vitamins Improves Cutaneous Hydration and Viscoelasticity in Healthy Subjects
by: Gabriel Siquier-Dameto, et al.
Published: (2024) -
Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain
by: Mireia Carcolé, et al.
Published: (2019) -
Puerarin Alleviates Neuropathic Pain by Inhibiting Neuroinflammation in Spinal Cord
by: Ming Liu, et al.
Published: (2014) -
Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain
by: Giacomo Rossino, et al.
Published: (2023) -
MMP24 Contributes to Neuropathic Pain in an FTO-Dependent Manner in the Spinal Cord Neurons
by: Longfei Ma, et al.
Published: (2021)